English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduKazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.
Tag: Clinical Data
Mayo Clinic and Mercy reach first major milestone in data collaboration
Mayo Clinic and Mercy are making a significant advancement in their global, first-of-its-kind 10-year collaboration agreement signed in the summer of 2022. As founding members of Mayo Clinic Platform_Connect, the two organizations will now be working together to analyze de-identified patient data as they search for new ways to diagnose, treat and prevent disease, providing better outcomes and lower costs of care.
UB pharmacy researcher aims to develop real-time algorithm to lower hospital readmission rates
To lower hospital readmission rates for patients with chronic obstructive pulmonary disease (COPD), University at Buffalo pharmacy researcher David Jacobs has received a $962,000 award from the National Heart, Lung, and Blood Institute to develop a real-time readmission risk prediction algorithm.
jCyte Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy
jCyte’s presentation at ARVO 2021, demonstrated that retinitis pigmentosa patients treated with the 6 million cell dose of jCell therapy had significant gains in a broad range of visual function tests – BCVA, visual field (KVF), contrast sensitivity (CS), and low luminance mobility (LLMT) – all which measure important and different aspects of functional vision. jCyte also engaged the Cleveland Clinic to identify an anatomical biomarker for patient response to jCell therapy in retinitis pigmentosa, which will help guide the upcoming pivotal study.